BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. METHODS: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. RESULTS: SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced ≥1 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with ≥1 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not ≥5. CONCLUSIONS: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginterferon alfa-2a/ribavirin. TRIAL REGISTRATION: ClinicalTrials.gov NCT01344889.

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort / Foster G.R.; Coppola C.; Derbala M.; Ferenci P.; Orlandini A.; Reddy K.R.; Tallarico L.; Shiffman M.L.; Ahlers S.; Bakalos G.; Hassanein T.; Basho J.; Shabanaj G.; Harxhi A.; Debzi N.; Afredj N.; Guessab N.; Mahindad N.; Mahiou H.; Aissaoui M.; Al Qameesh J.; Al Ghandoor Z.; Assene C.; Bastens B.; Brixko C.; Cool M.; De Galocsy C.; Delwaide J.; George C.; Laukens P.; Lefebvre V.; Mulkay J.-P.; Nevens F.; Servais B.; Van Vlierberghe H.; Horsmans Y.; Henrion J.; Sprengers D.; Michielsen P.; Bourgeois S.; Lasser L.; Langlet P.; Robaeys G.; Martinet J.-P.; Warzee P.; Hoste P.; Reynaert H.; Juriens I.; Decaestecker J.; Van Der Meersch F.; Janssens F.; Ahmetagic S.; Verhaz A.; Bevanda M.; Calkic L.; Ibrahimpasic N.; Mesihovic R.; Mello C.E.; Ruiz F.J.; Junior E.M.; Ferraz M.L.; Silva G.; Mendes C.; Lyra A.; Silva M.H.; Gomide G.; Fernandes J.C.; Pereira P.; Correa M.C.; Teixeira R.; Yousry A.; Hanno A.; Gabr M.; Omar A.; Esmat G.; Karatapanis S.; Nikolopoulou V.; Giannoulis G.; Manolakopoulos S.; Elefsiniotis I.; Drakoulis C.; Dimitroulopoulos D.; Kanatakis S.; Ketikoglou I.; Mimidis K.; Evgenidis N.; Akriviades E.; Vafiadi-Zoubouli I.; Tsianos E.; Mela M.; Orfanou E.; Mousoulis G.; Karagiannis I.; Manesis E.; Varga M.; Nemesanszky E.; Fried K.; Schuller J.; Szalay F.; Lengyel G.; Tornai I.; Banyai T.; Lesch M.; Nagy I.; Gervain J.; Tusnadi A.; Schneider F.; Szentgyorgyi L.; Hunyady B.; Vincze A.; Tolvaj G.; Varkonyi I.; Makkai E.; Enyedi J.; Racz I.; Hausinger P.; Vaczi Z.; Patai A.; Ozsvar Z.; Lakner L.; Ribiczey P.; Bhalla A.; Somani S.; Luaia R.; Rao P.; Philip M.; Lawate P.; Nagral A.; Sood A.; Parikh S.; Merat S.; Nassiri-Toosi M.; Alavian S.-M.; Zali M.R.; Daryani N.E.; Drenaggi D.; Attili A.F.; Bandiera F.; Bassi P.; Bellati G.; Bellantani S.; Brunetto M.; Bruno S.; Castelli F.; Castellacci R.; Cattelan A.M.; Colombo M.; Craxi A.; D'angelo S.; Colombo S.; Demelia L.; Di Perri G.; Di Giacomo A.; Ferrari C.; Francisci D.; Casinelli K.; Ganga R.; Costa C.; Mangia A.; Russo F.P.; Matarazzo F.; Mazzella G.; Mazzeo M.; Memoli M.; Montalbano M.; Montalto G.; Pieri A.; Passariello N.; Picciotto A.; Pietrangelo A.; Pirisi M.; Quirino T.; Raimondo G.; Rapaccini G.L.; Rizzardini G.; Rizzetto M.; Russello M.; Sabusco G.; Santantonio T.; Soardo G.; Amedea A.; Verucchi G.; Vinelli F.; Zignego A.L.; Zuin M.; Ascione A.; Vinci M.; Pigozzi M.G.; Tundo P.; Saracco G.M.; Amoroso P.; Andreoni M.; Colletta C.; Erne E.; Megna A.S.; Biglino A.; Chiriaco P.; Foti G.; Spinzi G.; D'amico E.; Paik S.W.; Ahn S.-H.; Lee Y.N.; Kim Y.; Yang J.; Han S.Y.; Varghese R.; Al Gharabally A.; Askar H.; Sharara A.; Yaghi C.; Abou Rached A.; Houmani Z.; Zaarour F.; Dohaibi A.; Ivanovski L.; Joksimovic N.; Abbas Z.; Memon S.; Mohsin A.; Masood S.; Hashmi Z.; Halota W.; Deron Z.; Mazur W.; Flisiak R.; Lipczynski A.; Musialik J.; Piekarska A.; Augustyniak K.; Baka-Cwierz B.; Simon K.; Gietka A.; Berak H.; Sieklucki J.; Radowska D.; Szlauer B.; Piekos T.; Olszok I.; Jablkowski M.; Orszulak G.; Warakomska I.; Aleixo M.J.; Valente C.; Macedo G.; Sarmento-Castro R.; Roxo F.; Faria T.; Mansinho K.; Velez J.; Ramos J.P.; Guerreiro H.; Alberto S.; Monteverde C.; Serejo F.; Peixe P.; Malhado J.; Curescu M.; Streinu-Cercel A.; Caruntu F.; Livia H.; Preotescu L.; Arama V.; Ancuta I.; Gheorghe L.; Stanciu C.; Trifan A.; Acalovschi M.; Andreica V.; Pascu O.; Lencu M.; Sporea I.; Olteanu D.; Ionita-Radu F.; Fierbinteanu-Braticevici C.; Motoc A.; Silaghi R.; Musat M.; Coman F.; Stan M.; Cijevschi C.; Miftode E.; Delic D.; Jesic R.; Nozic D.; Svorcan P.; Fabri M.; Konstantinovic L.; Pelemis M.; Jankovic G.; Todorovic Z.; Nagorni A.; Kupcova V.; Skladany L.; Szantova M.; Krkoska D.; Jarcuska P.; Schreter I.; Oltman M.; Bocakova J.; Bunganic I.; Holoman J.; Giguere A.; Abdou A.M.S.. - In: PLOS ONE. - ISSN 1932-6203. - ELETTRONICO. - 11:(2016), pp. e0151703-0. [10.1371/journal.pone.0151703]

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort

George C.;SILVA DE OLIVEIRA, GERTRUDES MARIA FELICIDADE;MENDES, LUDJERO NUNO CATY;RAO, DODLA SAI PRASADA;CASTELLACCI, RICCARDO;COLOMBO, SIMONA;DE FRANCISCI, DOMENICO;Russo F. P.;MATARAZZO, FRANCESCA;MAZZEO, MARCO;Memoli M.;Zignego A. L.;Foti G.;YANG, JINGJING;Fabri, Marco;
2016

Abstract

BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. METHODS: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. RESULTS: SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced ≥1 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with ≥1 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not ≥5. CONCLUSIONS: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginterferon alfa-2a/ribavirin. TRIAL REGISTRATION: ClinicalTrials.gov NCT01344889.
2016
11
e0151703
0
Foster G.R.; Coppola C.; Derbala M.; Ferenci P.; Orlandini A.; Reddy K.R.; Tallarico L.; Shiffman M.L.; Ahlers S.; Bakalos G.; Hassanein T.; Basho J.; Shabanaj G.; Harxhi A.; Debzi N.; Afredj N.; Guessab N.; Mahindad N.; Mahiou H.; Aissaoui M.; Al Qameesh J.; Al Ghandoor Z.; Assene C.; Bastens B.; Brixko C.; Cool M.; De Galocsy C.; Delwaide J.; George C.; Laukens P.; Lefebvre V.; Mulkay J.-P.; Nevens F.; Servais B.; Van Vlierberghe H.; Horsmans Y.; Henrion J.; Sprengers D.; Michielsen P.; Bourgeois S.; Lasser L.; Langlet P.; Robaeys G.; Martinet J.-P.; Warzee P.; Hoste P.; Reynaert H.; Juriens I.; Decaestecker J.; Van Der Meersch F.; Janssens F.; Ahmetagic S.; Verhaz A.; Bevanda M.; Calkic L.; Ibrahimpasic N.; Mesihovic R.; Mello C.E.; Ruiz F.J.; Junior E.M.; Ferraz M.L.; Silva G.; Mendes C.; Lyra A.; Silva M.H.; Gomide G.; Fernandes J.C.; Pereira P.; Correa M.C.; Teixeira R.; Yousry A.; Hanno A.; Gabr M.; Omar A.; Esmat G.; Karatapanis S.; Nikolopoulou V.; Giannoulis G.; Manolakopoulos S.; Elefsiniotis I.; Drakoulis C.; Dimitroulopoulos D.; Kanatakis S.; Ketikoglou I.; Mimidis K.; Evgenidis N.; Akriviades E.; Vafiadi-Zoubouli I.; Tsianos E.; Mela M.; Orfanou E.; Mousoulis G.; Karagiannis I.; Manesis E.; Varga M.; Nemesanszky E.; Fried K.; Schuller J.; Szalay F.; Lengyel G.; Tornai I.; Banyai T.; Lesch M.; Nagy I.; Gervain J.; Tusnadi A.; Schneider F.; Szentgyorgyi L.; Hunyady B.; Vincze A.; Tolvaj G.; Varkonyi I.; Makkai E.; Enyedi J.; Racz I.; Hausinger P.; Vaczi Z.; Patai A.; Ozsvar Z.; Lakner L.; Ribiczey P.; Bhalla A.; Somani S.; Luaia R.; Rao P.; Philip M.; Lawate P.; Nagral A.; Sood A.; Parikh S.; Merat S.; Nassiri-Toosi M.; Alavian S.-M.; Zali M.R.; Daryani N.E.; Drenaggi D.; Attili A.F.; Bandiera F.; Bassi P.; Bellati G.; Bellantani S.; Brunetto M.; Bruno S.; Castelli F.; Castellacci R.; Cattelan A.M.; Colombo M.; Craxi A.; D'angelo S.; Colombo S.; Demelia L.; Di Perri G.; Di Giacomo A.; Ferrari C.; Francisci D.; Casinelli K.; Ganga R.; Costa C.; Mangia A.; Russo F.P.; Matarazzo F.; Mazzella G.; Mazzeo M.; Memoli M.; Montalbano M.; Montalto G.; Pieri A.; Passariello N.; Picciotto A.; Pietrangelo A.; Pirisi M.; Quirino T.; Raimondo G.; Rapaccini G.L.; Rizzardini G.; Rizzetto M.; Russello M.; Sabusco G.; Santantonio T.; Soardo G.; Amedea A.; Verucchi G.; Vinelli F.; Zignego A.L.; Zuin M.; Ascione A.; Vinci M.; Pigozzi M.G.; Tundo P.; Saracco G.M.; Amoroso P.; Andreoni M.; Colletta C.; Erne E.; Megna A.S.; Biglino A.; Chiriaco P.; Foti G.; Spinzi G.; D'amico E.; Paik S.W.; Ahn S.-H.; Lee Y.N.; Kim Y.; Yang J.; Han S.Y.; Varghese R.; Al Gharabally A.; Askar H.; Sharara A.; Yaghi C.; Abou Rached A.; Houmani Z.; Zaarour F.; Dohaibi A.; Ivanovski L.; Joksimovic N.; Abbas Z.; Memon S.; Mohsin A.; Masood S.; Hashmi Z.; Halota W.; Deron Z.; Mazur W.; Flisiak R.; Lipczynski A.; Musialik J.; Piekarska A.; Augustyniak K.; Baka-Cwierz B.; Simon K.; Gietka A.; Berak H.; Sieklucki J.; Radowska D.; Szlauer B.; Piekos T.; Olszok I.; Jablkowski M.; Orszulak G.; Warakomska I.; Aleixo M.J.; Valente C.; Macedo G.; Sarmento-Castro R.; Roxo F.; Faria T.; Mansinho K.; Velez J.; Ramos J.P.; Guerreiro H.; Alberto S.; Monteverde C.; Serejo F.; Peixe P.; Malhado J.; Curescu M.; Streinu-Cercel A.; Caruntu F.; Livia H.; Preotescu L.; Arama V.; Ancuta I.; Gheorghe L.; Stanciu C.; Trifan A.; Acalovschi M.; Andreica V.; Pascu O.; Lencu M.; Sporea I.; Olteanu D.; Ionita-Radu F.; Fierbinteanu-Braticevici C.; Motoc A.; Silaghi R.; Musat M.; Coman F.; Stan M.; Cijevschi C.; Miftode E.; Delic D.; Jesic R.; Nozic D.; Svorcan P.; Fabri M.; Konstantinovic L.; Pelemis M.; Jankovic G.; Todorovic Z.; Nagorni A.; Kupcova V.; Skladany L.; Szantova M.; Krkoska D.; Jarcuska P.; Schreter I.; Oltman M.; Bocakova J.; Bunganic I.; Holoman J.; Giguere A.; Abdou A.M.S.
File in questo prodotto:
File Dimensione Formato  
journal.pone.0151703.PDF

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 1.07 MB
Formato Adobe PDF
1.07 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1168917
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact